key: cord-0336348-mj6947sy
authors: Mousavian, Z.; Folkesson, E.; Froberg, G.; Foroogh, F.; Correia-Neves, M.; Bruchfeld, J.; Kallenius, G.; Sundling, C.
title: A protein signature associated with active tuberculosis identified by plasma profiling and network-based analysis
date: 2022-04-22
journal: nan
DOI: 10.1101/2022.04.22.22274170
sha: bc6cec0dd7f3b3b7bb30ae95fc4c346ab6e7e7e5
doc_id: 336348
cord_uid: mj6947sy

Objectives: Tuberculosis (TB) is a bacterial infectious disease caused by Mycobacterium tuberculosis. Annually, an estimated 10 million people are diagnosed with active TB, and approximately 1.4 million dies of the disease. If left untreated, each person with active TB will infect 10 to 15 new individuals every year. Therefore, interrupting disease transmission by accurate early detection and diagnosis, paired with appropriate treatment is of major importance. In this study, we aimed to identify biomarkers associated with the development of active TB that can then be further developed for clinical testing. Methods: We assessed the relative plasma concentration of 92 proteins associated with inflammation in individuals with active TB (n=19), latent TB (n=13), or healthy controls (n=10). We then constructed weighted protein co-expression networks to reveal correlations between protein expression profiles in all samples. After clustering the networks into four modules, we assessed their association with active TB. Results: One module consisting of 16 proteins was highly associated with active TB. We used multiple independent transcriptomic datasets from studies investigating respiratory infections and non-TB diseases. We then identified and removed genes encoding proteins within the module that were low expressed in active TB or associated with non-TB diseases, resulting in a 12-protein plasma signature associated with active TB. Conclusion: We identified a plasma protein signature that is highly enriched in patients with active TB but not in individuals with latent TB or healthy controls and that also had minimal cross-reactivity with common viral or bacterial lower respiratory tract infections.

Materials and methods: 105 106

Ethical considerations 107

The study was registered and granted ethical permission from the Swedish Ethical Review 108

Board, EPN-number 2013/1347-31/2 and 2017/2262-32. All study subjects signed written 109 informed consent forms after receiving written and verbal information, in relevant cases 110 using professional interpreter services. 111 112

Study participants 113

Patients were recruited at the Karolinska University Hospital, Stockholm from May 2018 to 114

November 2019. Eligible for the study were: 1) Active TB patients within seven days of 115 treatment initiation. Active TB was defined through microbiological verification via Mtb 116 culture, or if culture negative, other microbiological positive result for Mtb (microscopy or 117 PCR) combined with clinical and radiological findings and response to anti-TB treatment 118

(active TB individuals are further described in Table S1 ); 2) Latent TB individuals with a 119 positive IGRA result (QuantiFERON-TB Gold In-Tube (QFT-GIT) or QuantiFERON-TB 120

Gold Plus (QFT-Plus) identified through contact investigation or screening of migrants, for 121 which active TB had been excluded. The cut-off between recent and remote TB was set to 122 two years after exposure; 3) Healthy controls with a negative IGRA-result and without 123 previously known TB-exposure, co-morbidities, or immunosuppression. 124 125

Data collection 126

Demographic, epidemiological, and clinical data for patients with active and latent TB were 127 extracted from patient charts. For all subjects this included information regarding previous 128 exposure to patients with active TB or infection, comorbidities and current medication, 129 radiological, biochemical, and microbiological test results. For the active TB cases, clinical 130 symptoms of TB disease were noted, and patients were classified according to pulmonary or 131 extrapulmonary TB. Microbiological samples for mycobacterial analysis were collected 132 independent of the study in accordance with clinical practice. 133 134

Analysis of plasma proteins by proximity extension assay 135 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Venous blood samples were collected in heparin vacutainer tubes and transferred to the 136 laboratory for immediate preparation. The tubes were centrifuged at 670 g for 8 min after 137 which the plasma fraction was aliquoted and stored at -80 °C. 138

Patient plasma was analysed using the Olink proximity extension assay, a qPCR 139 technology that simultaneously measures combinations of cytokines in preselected panels. 140 We used the 96-protein inflammatory panel, analysing 92 protein biomarkers and 4 controls 141 (Table S2 ). In this automated process, specific antibodies carrying single stranded matching 142 DNA bind in pairs to each of the target proteins allowing for DNA hybridization and 143

subsequent DNA-extension. The resulting DNA, unique for each target protein, is then 144 subject to PCR amplification and finally detection. The generated results consist of 145 normalized protein expression (NPX) values that correspond to log2 transformed relative 146 protein concentrations. The assay was performed by the Translational Plasma Profile Facility 147

at SciLifeLab, Stockholm, Sweden. 148 149

Protein expression data analysis 150

Repeated samples were used between experimental batches for running bridge normalization. 151

We used read_NPX and olink_normalization functions from the OlinkAnalyze R package 152

(https://github.com/Olink-Proteomics/OlinkRPackage) to read the log2 NPX protein 153 expression values and perform bridge normalization between batches of our data respectively. 154

Proteins with NPX values below the limit of detection (LOD) in more than 30% of samples 155

were filtered out. To remove batch effects from the final dataset, we applied the 156 removeBatchEffect function from the Limma R package (15) ( Figure S1 ). We also performed 157 differential expression analysis using the Limma R package. 158 159

Weighted co-expression network analysis 160 We used the WGCNA R package to construct a weighted protein co-expression network 161 among the proteins of our dataset. Pearson correlation and the signedhybrid network type 162

were used in the adjacency function of the WGCNA package. In the signedhybrid network 163 type, only links associated to positive correlations were retained in the network, and negative 164 correlations were discarded. Since most of the biological networks have a scale-free 165 topology, the WGCNA package in the pickSoftThreshold function tries to find the best value 166 of the power parameter to make a scale-free network. After network construction, the 167 network was clustered into modules containing proteins that were highly positively co-168 expressed using a hierarchical clustering algorithm as implemented in the cutreeDynamic 169 function of the WGCNA package with parameters deepSplit = 4 and minClusterSize = 5, and 170 other parameters set as default. The expression profiles of proteins in each module were 171 summarized by module eigengenes. In the moduleEigengenes function from the WGCNA 172 package, the first principal component of the expression data of each module is measured as a 173 module eigengene for that module. To find a module associated with TB progression, the 174 correlation between each module eigengene and the trait vector was computed to identify 175 which module that had a significant correlation with TB progression. 176 177

Protein signature enrichment analysis 178

To further validate the protein signature obtained from the co-expression network analysis, 179

we applied two computational methods (ssGSEA and QuSAGE) for enrichment analysis in 180 independent transcriptomic datasets. In ssGSEA, the enrichment scores of the protein 181 signature were calculated per sample based on the absolute value of proteins expression in 182 that sample to quantify how much the protein signature was overrepresented in a specific 183 sample. Moreover, to verify that the protein signature was specific to active TB and not to 184 other non-TB respiratory infections or diseases with clinical presentations similar to active 185 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 TB, the qusage function from the QuSAGE R package was applied to datasets comparing 186 active TB or non-TB disease to various control groups. The gene set differential expression 187 was calculated by combining individual probability functions obtained from individual 188 differential expression of genes in a particular comparison. A p-value, calculated by 189

QuSAGE, determined the statistical significance of a gene set for each given comparison. We 190 also used different types of single sample gene set enrichment analysis algorithms, including 191 ssGSEA, GSVA (16) and zscore (17), all implemented in the gsva R package, to compare all 192 co-expressed modules in terms of enrichment in active TB versus latent TB and healthy 193 controls. 194 195 Results 196 197 Clinical characteristics of the study participants 198

The plasma of 21 individuals with active TB, 16 individuals with latent TB, and 10 healthy 199 controls were analyzed using the Olink inflammation proximity extension assay. During data 200 processing, 5 samples (2 active TB and 3 latent TB) were excluded for either failing the 201 quality control check included in the OlinkRPackage or identified as outliers by cluster 202 analysis ( Figure S2 ). The characteristics of the remaining study participants are further 203 described in Table 1 . 204

As a reflection of the low TB incidence in Sweden, most study individuals originated 205 from other countries, mainly situated in Africa, Asia and Eastern Europe. Fifteen of 19 active 206 cases had pulmonary TB including 3 with pleuritis, 6 of which were sputum smear positive. 207

Four had extrapulmonary TB cases of which two with disseminated disease. Only 1 out of the 208 19 active TB patients was not confirmed by microbiologic culture; this patient had a positive 209 PCR for M. tuberculosis in a lymph node aspirate and gastric lavage as well as radiologic 210 signs of active pulmonary TB and showed a clinical response to TB-treatment. The active TB 211 cases were sampled within one week of treatment initiation except for one patient that was 212 sampled at day 9. Of the 13 latent TB patients, 10 had a known recent TB exposure 1-4 213 months prior to study inclusion. All but 2 latent TB individuals completed preventive TB 214 treatment, and none progressed to active TB during a follow up period of > 2 years. There 215

were few significant co-morbidities, with no patient in either group on immunosuppressive 216 treatment. All active TB patients were HIV negative. The latent TB and healthy controls were 217 not routinely tested for HIV infection. 218

From the 10 healthy controls, 1 had a QFT-Gold Plus result in the low range of the 219 borderline interval (0.35-0.99 IU/ml) but with no known exposure, potentially indicating a 220 false positive result (18, 19) . 221 222 223

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 ( m e a n , r a n g e )

Patient origins; Active TB: Somalia (4) Eritrea (3) Following data pre-processing, including quality control, batch correction, and clustering the 242 relative level (NPX) of each of the 92 proteins was assessed. Proteins with more than 30% of 243 samples with NPX values below the limit of detection (n = 28) were excluded from further 244 analysis. Out of those 28 proteins, 25 had no differential expression between the groups 245 ( Figure S3 ). A weighted protein co-expression network was constructed with the remaining 246 64 proteins to examine correlations between protein expression profiles in all included 247 samples (n = 42 individuals). We considered only the links associated with positive 248 correlations in the network reconstruction and selected power 8 to reach a scale-free topology 249 ( Figure S4 ). After clustering the network into modules, four modules indicated by distinct 250 colours in Figure 2 were discovered (Table 2) , including 34 proteins. The remaining 30 251

proteins that were not included in any of the modules, were discarded from further analysis. 252 We observed that the turquoise module out of the four modules had a significantly stronger 253 correlation with active TB (Table 2) . A visual representation of the protein co-expression 254 network and the discovered protein modules were then generated using Cytoscape 3.0 (20) 255

( Figure 2 ). 256 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We then assessed how the markers differed between individuals with active TB, latent TB, 268

and healthy controls ( Figure S5 ). All differentially expressed proteins (log2(FC) ≥ 1 and 269

FDR-corrected p-value < 0.01) between either active TB and latent TB or active TB and 270 healthy controls except FGF-21 and EN-RANGE were included in the turquoise module 271 (Figure 3 ). Eight of the 16 proteins in the turquoise module were highly expressed in active 272 TB patients while the remaining 8 proteins were strongly co-expressed with those highly 273 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Validating the turquoise module in independent transcriptomic TB datasets 287

There is limited overlap in markers between studies investigating protein or gene signatures 288 aiming to discriminate active TB from latent TB, healthy controls, or other diseases ( Figure  289 S7). Additionally, we did not identify any available pre-processed proteomic dataset 290 including all proteins of the turquoise module that we could use for validation. For this 291 reason, we chose to instead evaluate to what extent the proteins of the different modules 292 could distinguish active TB from latent TB and healthy controls in transcriptomic datasets. 293 We applied all four modules to several independent cohorts using multiple gene set 294 enrichment analysis methods. Nine transcriptomic TB datasets were selected based on the 295 criteria of age >15, number of individuals per group >10 and no anti-TB treatment (Table  296 S3). The datasets were provided in the curatedTBData R package (21), which also included 297

the corresponding genes to all proteins included in the four modules. In total the datasets we 298 selected included >3000 individuals from four continents. Three enrichment methods (ssgsea, 299 gsva and zscore) demonstrated high enrichment of the turquoise module in active TB and low 300 enrichment in latent TB and the control group across most of the TB datasets (Figures S8-301 S10). This was also the case for the blue module, although to a less extent compared with the 302 turquoise module. In contrast, neither the brown nor yellow modules were found highly 303 enriched in active TB using the same three methods on the same transcriptomic datasets 304

( Figures S8-S10 ). 305 306

Identification of a new 12-protein signature for active TB diagnosis 307

We identified the turquoise module as having the highest correlation with active TB. 308

However, two of the 16 proteins in the module, LAP TGF-beta-1 and CSF-1, had low fold 309 change values (log2(FC) < 0.5) when comparing active TB versus both latent TB and healthy 310 controls (Figure 3) , and were therefore potentially redundant. 311 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 To investigate if the remaining 14 proteins were specific for active TB, we performed 312 differential expression analysis using multiple transcriptomic datasets including either viral or 313 bacterial lower respiratory tract infections (LRTI), systemic inflammatory response syndrome 314 (SIRS) or sarcoidosis (Figure 4 ). This allowed us to identify genes encoding the signature 315 proteins that were highly and significantly expressed (log2(FC) > 1 and P-value < 0.05) in 316 diseases with clinical symptoms overlapping with active TB. To this end, we used three 317 transcriptomic datasets, GSE42026 (22), GSE40012 (23) and GSE60244 (24) and CXCL10 (IP-10), stood out in these analyses ( Figure 4 ). IL18R1 was highly expressed in 328 severe viral and bacterial LRTI and SIR, while CXCL10 was highly expressed in severe viral 329

LRTI and in one of the sarcoidosis studies. However, most of the proteins of the signature 330

were only observed to be expressed at high levels in individuals with active TB. Therefore, in 331 addition to LAP TGF-beta-1 and CSF-1 that were expressed only at very low levels, we also 332 removed IL18R1 and CXCL10 from the signature, leading to a 12-marker plasma signature 333 associated with active TB and with low cross-reactivity to other bacterial/viral lower 334 respiratory infections and sarcoidosis. The final signature consisted of the proteins IFN-335 gamma, IL6, CDCP1, CXCL9, MMP-1, MCP-3, CCL19, CD40, VEGFA, IL7, IL-12B and 336 PDL-1. 337

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Validating the 12-marker signature in TB and non-TB proteomic and transcriptomic 355 datasets 356

To assess the significance of the 12-marker signature in independent TB cohorts, we 357 performed ssGSEA on transcriptomic TB datasets from the curatedTBData R package (Table  358 S3). We observed significantly (p < 0.05) higher enrichment scores in the active TB group, 359 compared with either latent TB or controls in all the transcriptomic TB datasets except one 360 (GSE19444) ( Figure 5A ). We then used QuSAGE to compare the enrichment of the 12-361 marker signature in TB infections with both other bacterial/viral infections and other 362 pulmonary diseases ( Figure 5B ). Three different comparisons were done using the 363 GSE42026, GSE40012 and GSE60244 datasets to assess the signature in respiratory 364

infections versus healthy controls, and in sarcoidosis disease versus healthy controls using 365 three transcriptomic datasets (GSE83456, GSE42826 and GSE42830) ( Figure 5B ). We 366 observed that the 12-marker signature was significantly overrepresented (FDR corrected P-367 value < 0.05) in all comparisons between active TB and latent TB or healthy controls but was 368 not significantly enriched in those gene sets comparing other LRTIs vs. healthy controls. 369

However, in two of the three sarcoidosis datasets the signature was also enriched, indicating 370 that the signature might not, on its own, be able to distinguish active TB from sarcoidosis 371 without also weighing clinical data. 372

We then compared the 12-marker signature with the other published gene signatures 373 from the TBSignatureProfiler R package (28) and published protein signatures to investigate 374 overlap between protein and transcriptional signatures with the proteins of our signature 375 ( Figure 5C ). VEGFA, IL6, and IFN-gamma were identified in at least two other proteomic 376 studies (29-33), while CD274 (also called PD-L1) was observed in several published 377 transcriptional signatures. IP-10 (also called CXCL10), which was removed due to its high 378 expression in severe viral LRT and sarcoidosis appears in several proteomic studies (30-33). 379

The other markers were less common or identified in the current study. Although these 380

proteins have not been included in protein signatures before, they have been associated with 381 TB (34-37) and could potentially be generated via similar signaling pathways in response to 382 mycobacterial infection, such as has been indicated for signal transducer and activator of 383 transcription 1 (STAT1) in TB (38). To assess if this was the case, we used the StrongestPath 384 application (39) in Cytoscape to evaluate how the proteins were connected to different STAT 385 transcription factors based on data from the KEGG database ( Figure S11 ). We observed that 386 several of the proteins were directly associated with STAT1, consistent with previous 387 literature (38) to a lesser extent with STAT3 and STAT4, and indirectly with STAT2 and 388 STAT5A. 389 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Association between the 12-marker signature and disease severity 404

Principal component analysis of the 12-marker signature ( Figure 6A ) showed that, similar to 405 the turquoise module ( Figure S6 ), active TB was primarily separated from latent TB and 406 healthy controls by principal component 1 (PC1). We therefore hypothesized that PC1 could 407 represent a proxy for the magnitude of the inflammatory response and disease severity. To 408 evaluate if this was the case, we stratified the individuals with active TB based on their PC1 409 values and a set of clinical features ( Figure 6B ). The heatmap shows that samples with a 410 smaller PC1 value, located towards the left side of heatmap, were associated with several 411 biochemical markers indicating more extensive inflammation, such as lower hemoglobin 412

(Hb) and albumin (Alb), and higher erythrocyte sedimentation rate (ESR) and C-reactive 413 protein (CRP). The presence of any systemic symptoms (fever, night sweats and weight loss) 414

and smear positivity were also associated with a lower PC1 value. We next performed a 415 regression analysis to see if individual or combinations of the clinical variables could explain 416

the PC1 values. A standard least squares model including ESR (estimate: -0.03, 95% CI: -417 0.016 --0.044, p = 0.0008) and Alb (estimate: 0.21, 95% CI: 0.08-0.34, p = 0.006) were 418 highly associated with PC1 (r 2 = 0.74, p < 0.0001), clearly associating the signature with 419 clinical presentation (40). 420

The three active TB cases with the weakest PC1 signal had few symptoms and limited 421 disease activity and inflammation ( Figure 6A ). One patient had a culture-confirmed lymph 422 node TB. Another patient had a PCR positive but culture-negative lymph node and 423 pulmonary TB. The active TB case with the lowest inflammatory signal was found through 424 contact investigation very early in active disease progression with cough as the only symptom 425 but with no inflammation in laboratory tests. This suggests that the signature has the potential 426 to identify active TB very early on in the progression from latent TB. 427

Although the signature was not optimized for the detection of latent TB, the visually 428 apparent separation of latent TB from healthy controls ( Figure 6A ) could possibly indicate a 429 TB-specific immune response detectable in the plasma of these individuals. Two of the three 430 latent TB cases clustering with the healthy controls had no recent exposure to TB and were 431 clinically classified as remotely acquired infections (i.e., no known exposure to a TB case for 432 > 2 years). In summary, these data suggest that the signature could be helpful in identifying 433 TB disease progression or cure. 434 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Discussion 447

The purpose of this study was to identify a protein signature in plasma that was enriched in 448 individuals with active TB compared to those with latent infection and healthy controls. We 449 used the Olink PEA method to simultaneously measure 92 proteins in plasma. Using co-450 expression analysis, we could identify 16 proteins that were co-expressed and highly 451 correlated with active TB. To test the validity of these findings, we used publicly available 452 transcriptomic datasets. First, we removed two proteins with very low differential expression 453 between active TB and controls. We then refined the signature by excluding two additional 454 proteins that were highly expressed in other lower respiratory tract infections. This allowed 455 us to generate a 12-protein signature that was highly specific when applied to independent TB 456 datasets. When retesting the signature on our own data it also retained a similar 457 discriminatory capacity as the initial 16-protein signature. 458 459

Albeit small, the study cohort is well defined, with microbiological verification of all active 460 TB cases, a wide range of disease severity and with large variation in patient origin, 461

reflecting the TB population in Sweden and thus increasing the likelihood of generalizability 462

to other geographic regions. Further, results were validated in nine transcriptomic data sets 463

including over 3000 individuals from four continents. 464

On an individual patient level, the signature was associated with disease activity with 465 a stronger protein signature significantly related to perturbations in common clinical 466 inflammatory markers (ESR and albumin) and reported symptoms. 467 468 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 We have shown that the identified signature is differentially expressed in independent TB 469 transcriptomic datasets and importantly, it is not expressed in patients with other lower 470 respiratory tract infections, which is essential if the signature is to be used as a diagnostic 471 screening test in a clinical setting as intended. However, when testing the signature in a 472 sarcoidosis dataset (27) compared with healthy controls in our dataset ( Figure S5 ), the fold-change values were low 499 compared with the proteins included in the 12-protein signature and were not significantly 500

higher when compared with latent TB individuals. 501 VEGF was also included in a 4-protein signature (CCL1, CXCL10, ADA-2, VEGF) 502

proposed by Delemarre et al. (30) , where they compared active TB to treated and untreated 503 latent TB. The signature was validated in two separate patient cohorts with a sensitivity of 504 95% and a specificity of 90%. CXCL10 was also highly expressed in our analysis but was 505 removed due to its high expression in other lower respiratory tract infections. CCL1 and 506

ADA-2 were not analyzed in the current study. 507

Although VEGF was not included in the Chegou et al. (31) 7-protein signature, it was 508 increased in active TB patients in their cohort. Of their 7 proteins, IFN-gamma overlaps with 509 our 12-protein signature. CXCL10 (IP-10) again appears in their signature while the other 510 proteins (CRP, TTR, CFH, APO-A1, SSA) were not part of the proteins evaluated in our 511 study. 512

In 2021, Morris et al. (32) and Mutavhatsindi et al. (51) investigated the same 22 proteins as 513 Chegou et al. (31) and attempted to validate the 7-protein signature in patients with suspected 514

TB. In the first study, the sensitivity was very high (98%) while the specificity was low 515 (12%). They argued that this might be due to the different patient cohorts -primary care level 516 versus hospital care level. Instead, they identified a 9-protein signature (fibrinogen, alpha-2-517 macroglobulin, CRP, MMP-9, transthyretin, complement factor H [CFH], IFN-gamma, IP-518 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) including miR-29a, miR-146a, miR-99b and miR-221. IP-10 is also part of the 5-protein 527 signature identified by Luo et al. (52) . 528

Garay-Baquero et al., analyzed more than 5000 peptides using Mass spectrometry on 529 a relatively small discovery cohort (10 individuals with active TB and 10 healthy controls) 530

(44). They identified 46 proteins to be overexpressed in active TB and selected 9 and 7 531 proteins for validation in larger populations in South Africa and the UK, respectively. They 532 used Luminex or ELISA and compared active TB to other respiratory diseases (ORD) and 533 healthy controls. The proposed 5 protein signature; CFHR5, LRG1, CRP, LBP, and SAA1, 534

performed well with an AUC > 0.8 in both settings for active TB vs ORD. There was no 535 overlap with the 12-protein signature identified here, and none of the proteins were among 536 the 136 proteins identified as associated with active TB (46 more abundant and 90 less 537 abundant) in their discovery phase, although the use of different methods makes direct 538 comparison difficult. 539

Another large proteomic study by de Groote et al., (53) used SOMAscan to measure 540 over 4000 proteins in 1470 patient samples from pulmonary TB patients and other TB suspect 541 cases and resulted in a 6-protein signature. Although their signature did not overlap with our 542 12-protein signature, IL-6 and MMP-1 were overexpressed in their active TB cases. 543

In summary, IFN-gamma, IL-6, and VEGF, together with IP-10 were identified as 544 markers for active TB in several previous studies, as well as identified in our study. These are 545 all regulated by STAT-1, which has previously been identified as an important immune 546 response pathway in Mtb infection (38), and potentially explains why these proteins are 547

identified in different studies. However, as found here, IP-10 is also highly expressed in other 548

severe infectious diseases and as such is likely not specific for TB in the absence of Mtb-549 specific stimulation (54). 550 551

To conclude, we identified a plasma biomarker signature associated with active TB 552 progression that was further corroborated in several independent datasets. Although the 553 signature can likely be optimized further by testing it in independent protein datasets, the 554 included biomarkers warrant further investigation and development for diagnostic purposes, 555 which will be critical to stopping the TB pandemic. 556 557

Acknowledgements 558

We would foremost like to thank the study participants for agreeing to be included in the 559 study and donate study material. We would also like to thank the study nurses Monica 560

Modin, Jan Bellbrant, Anna Dahlberg and Lena Jansson for patient inclusion, Julius 561

Lautenbach and Victor Yman for constructive discussions about the analysis, and the 562 SciLifeLab Translational Plasma Profiling facility for their support and generating data for 563 this study. This study was supported by grants from the Swedish Research Council . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

Tuberculosis Diagnostics: State of the Art and Future 571 Directions

Advances in the diagnosis of tuberculosis: current status and future 573 prospects. The international journal of tuberculosis and lung disease : the official journal of 574 the International Union against

The global prevalence of latent 576 tuberculosis: a systematic review and meta-analysis

Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic 579 review

Ultra for pulmonary tuberculosis and rifampicin resistance in 582 adults

Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in 585 adults with presumptive pulmonary tuberculosis

Delay in diagnosis of and a 593 framework for evaluation for a test for predicting progression from tuberculosis infection to 594 active disease. World Health Organization. License: CC BY-NC-SA 3.0 IGO

Diagnostic 'omics' for active 596 tuberculosis

High-throughput and computational approaches for 598 diagnostic and prognostic host tuberculosis biomarkers

Genome-wide expression for diagnosis 600 of pulmonary tuberculosis: a multicohort analysis

A 380-gene 602 meta-signature of active tuberculosis compared with healthy controls

limma powers 608 differential expression analyses for RNA-sequencing and microarray studies

GSVA: gene set variation analysis for 611 microarray and RNA-seq data

Inferring pathway activity toward 613 precise disease classification

A borderline 615 range for Quantiferon Gold In-Tube results

The Impact of Borderline Quantiferon-TB Gold Plus Results for Latent Tuberculosis 618

Screening under Routine Conditions in a Low-Endemicity Setting

Cytoscape: a 621 software environment for integrated models of biomolecular interaction networks

curatedTBData: Curation of existing 49 tuberculosis transcriptomic studies

Transcriptomic profiling in childhood H1N1/09 influenza reveals reduced expression of 628 protein synthesis genes. The Journal of infectious diseases

A 630 distinct influenza infection signature in the blood transcriptome of patients with severe 631 community-acquired pneumonia

Superiority of 633 transcriptional profiling over procalcitonin for distinguishing bacterial from viral lower 634 respiratory tract infections in hospitalized adults

Systemic Inflammatory Response Syndrome. StatPearls. 637 Treasure Island (FL)2022. 638 26

Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, 640 pneumonias and lung cancers

The 642 Transcriptional Signature of Active Tuberculosis Reflects Symptom Status in Extra-643 Pulmonary and Pulmonary Tuberculosis

A rapid triage test 648 for active pulmonary tuberculosis in adult patients with persistent cough

Ottenhoff 651 THM, et al. Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine

Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis. 653 Front Immunol

Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of 656 active TB disease in African primary healthcare clinic attendees with signs and symptoms 657 suggestive of TB

High sensitivity 662 and specificity of a 5-analyte protein and microRNA biosignature for identification of active 663 tuberculosis

Anti-vascular 665 endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and 666 improves small molecule delivery

Plasma chemokines are biomarkers of disease severity, higher bacterial burden and delayed 669 sputum culture conversion in pulmonary tuberculosis

The prognosis of latent tuberculosis: 671 can disease be predicted?

Mycobacterium tuberculosis triggers formation of lymphoid structure in murine lungs. The 674 Journal of infectious diseases

STAT1 and its related molecules as potential 676 biomarkers in Mycobacterium tuberculosis infection

678 StrongestPath: a Cytoscape application for protein-protein interaction analysis

Sedimentation 681 rate and suPAR in relation to disease activity and mortality in patients with tuberculosis. The 682 international journal of tuberculosis and lung disease : the official journal of the International 683 Union against Tuberculosis and Lung Disease

Identification of diagnostic markers for tuberculosis by proteomic 691 fingerprinting of serum

Comprehensive plasma proteomic profiling reveals biomarkers for active tuberculosis

Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of 697 Latent Tuberculosis Infection

Screening and identification 699 of potential protein biomarkers for evaluating the efficacy of intensive therapy in pulmonary 700 tuberculosis

Proteomic profiling for plasma 702 biomarkers of tuberculosis progression

Serum proteomics of active tuberculosis patients and contacts reveals unique processes 705 activated during Mycobacterium tuberculosis infection

Proteomics Identifies Novel Plasma Biomarkers for Distinguishing Pulmonary Tuberculosis 708 and Latent Infection

Serum protein S100A9, SOD3, and 710 MMP9 as new diagnostic biomarkers for pulmonary tuberculosis by iTRAQ-coupled two-711 dimensional LC-MS/MS

Validation and Optimization of Host Immunological Bio-Signatures for a 714 Point-of-Care Test for TB Disease

Diagnostic performance of 716 plasma cytokine biosignature combination and MCP-1 as individual biomarkers for 717 differentiating stages Mycobacterium tuberculosis infection

Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of 721

Active Pulmonary Tuberculosis

A 723 multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of 724 infection with M. tuberculosis